The Asia Pacific prostate cancer nuclear medicine market is expected to grow from US$ 156.10 million in 2022 to US$ 295.37 million by 2028; it is estimated to grow at a CAGR of 11.2% from 2022 to 2028.
Nuclear medicine is mostly used to diagnose cardiovascular disease and cancer. Since the nuclear medicine industry is saturated, many companies and stakeholders are focusing on extending radiopharmaceutical uses in general. The demand and uptake of radiopharmaceuticals are projected to rise as their application areas grow, which would help businesses broaden their product lines and market share in neurological applications in the coming years. PET is a noninvasive nuclear imaging method for cancer diagnosis, staging, and treatment monitoring. PET imaging is done by injecting a positron-tagged radiopharmaceutical into a patient, usually intravenously. Precise imaging may aid physicians in providing better treatment in the era of individualized cancer treatments. The use of modern imaging is growing as it helps get accurate local staging and early metastatic cancer discovery, accurate oligometastatic disease identification, and optimal therapy response assessment. Next-generation imaging modalities, such as whole-body MRI and molecular imaging with combined PET and CT and PET and MRI combination employing innovative radiopharmaceuticals, provide new imaging options for patients with advanced prostate cancer.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC prostate cancer nuclear medicine market. The APAC prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
ImaginAb; Curium; Jubilant Radiopharma; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the APAC prostate cancer nuclear medicine market.
Nuclear medicine is mostly used to diagnose cardiovascular disease and cancer. Since the nuclear medicine industry is saturated, many companies and stakeholders are focusing on extending radiopharmaceutical uses in general. The demand and uptake of radiopharmaceuticals are projected to rise as their application areas grow, which would help businesses broaden their product lines and market share in neurological applications in the coming years. PET is a noninvasive nuclear imaging method for cancer diagnosis, staging, and treatment monitoring. PET imaging is done by injecting a positron-tagged radiopharmaceutical into a patient, usually intravenously. Precise imaging may aid physicians in providing better treatment in the era of individualized cancer treatments. The use of modern imaging is growing as it helps get accurate local staging and early metastatic cancer discovery, accurate oligometastatic disease identification, and optimal therapy response assessment. Next-generation imaging modalities, such as whole-body MRI and molecular imaging with combined PET and CT and PET and MRI combination employing innovative radiopharmaceuticals, provide new imaging options for patients with advanced prostate cancer.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC prostate cancer nuclear medicine market. The APAC prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
APAC Prostate cancer nuclear medicine Market Segmentation
The APAC prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the APAC prostate cancer nuclear medicine market is segmented into PET and SPECT. The PET dominated the APAC prostate cancer nuclear medicine market in 2022. Based on PET product, the APAC prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the APAC prostate cancer nuclear medicine market in 2022. Based on end user, the APAC prostate cancer nuclear medicine market is segmented into hospitals, clinics, and others. The hospitals segment dominated the APAC prostate cancer nuclear medicine market in 2022. Based on country, the APAC prostate cancer nuclear medicine market is segmented into China, Japan, India, South Korea, Australia, and the Rest of APAC. The China segment dominated the APAC prostate cancer nuclear medicine market in 2022.ImaginAb; Curium; Jubilant Radiopharma; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the APAC prostate cancer nuclear medicine market.
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Prostate Cancer Nuclear Medicine Diagnostics Market - By Type
1.3.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market - By PET Product
1.3.3 APAC Prostate Cancer Nuclear Medicine Diagnostics Market - By End User
1.3.4 APAC Prostate Cancer Nuclear Medicine Diagnostics Market - By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Prostate Cancer Nuclear Medicine Diagnostics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 APAC PEST Analysis
4.3 Experts Opinion
5. APAC Prostate Cancer Nuclear Medicine Diagnostics Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Developing Prevalence of Prostate Cancer
5.1.2 Growing Demand for Early and Precise Diagnosis of Prostate Cancer
5.2 Market Restraints
5.2.1 High Price Related to the Prostate Cancer Diagnostics and Treatment
5.3 Market Opportunities
5.3.1 Increasing Use of Radiopharmaceuticals in Prostate Cancer
5.4 Future Trends
5.4.1 Growing Research Activities for Development of Innovative Imaging Agents
5.5 Impact Analysis
6. Prostate Cancer Nuclear Medicine Diagnostics Market- APAC Analysis
6.1 APAC Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis
7. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Analysis - By Type
7.1 Overview
7.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)
7.3 SPECT
7.3.1 Overview
7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.4 PET
7.4.1 Overview
7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
8. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Analysis - By PET Product
8.1 Overview
8.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)
8.3 F-18
8.3.1 Overview
8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4 C-11
8.4.1 Overview
8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.5 GA 68 PSMA
8.5.1 Overview
8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9. APAC Prostate Cancer Nuclear Medicine Diagnostics Market - By End User
9.1 Overview
9.2 APAC Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10. APAC Prostate Cancer Nuclear Medicine Diagnostics Market - By Country Analysis
10.1 APAC: Prostate Cancer Nuclear Medicine Diagnostics Market
10.1.1 Overview
10.1.2 APAC: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
10.1.2.1 China: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 China: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.3 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019-2028 (US$ Million)
10.1.2.1.4 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019-2028 (US$ Million)
10.1.2.1.5 China: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019-2028 (US$ million)
10.1.2.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.3 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019-2028 (US$ Million)
10.1.2.2.4 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019-2028 (US$ Million)
10.1.2.2.5 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019-2028 (US$ million)
10.1.2.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 India: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019-2028 (US$ Million)
10.1.2.3.4 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019-2028 (US$ Million)
10.1.2.3.5 India: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019-2028 (US$ million)
10.1.2.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.1 Overview
10.1.2.4.2 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.3 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019-2028 (US$ Million)
10.1.2.4.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019-2028 (US$ Million)
10.1.2.4.5 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019-2028 (US$ million)
10.1.2.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.1 Overview
10.1.2.5.2 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.3 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019-2028 (US$ Million)
10.1.2.5.4 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019-2028 (US$ Million)
10.1.2.5.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019-2028 (US$ million)
10.1.2.6 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.1 Overview
10.1.2.6.2 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.3 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019-2028 (US$ Million)
10.1.2.6.4 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019-2028 (US$ Million)
10.1.2.6.5 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019-2028 (US$ million)
11. Prostate Cancer Nuclear Medicine Diagnostics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 ImaginAb
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Curium
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Jubilant Radiopharma
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ABX advanced biochemical compounds GmbH
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Telix Pharmaceuticals Ltd.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Novartis AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Lantheus Medical Imaging, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms
List of Figures
Figure 1. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation
Figure 2. APAC Prostate Cancer Nuclear Medicine Diagnostics Market, By Country
Figure 3. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Overview
Figure 4. PET Segment Held Largest Share of Type Segment in Prostate Cancer Nuclear Medicine Diagnostics Market
Figure 5. China is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. APAC: PEST Analysis
Figure 7. APAC Experts Opinion
Figure 8. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Impact Analysis of Drivers and Restraints
Figure 9. APAC Prostate Cancer Nuclear Medicine Diagnostics Market- Revenue Forecast and Analysis - 2022 - 2028
Figure 10. APAC Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2022 & 2028 (%)
Figure 11. APAC SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. APAC PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. APAC Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2022 & 2028 (%)
Figure 14. APAC F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. APAC C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. APAC GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. APAC Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User - 2022 & 2028 (%)
Figure 18. APAC Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. APAC Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. APAC Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. APAC: Prostate Cancer Nuclear Medicine Diagnostics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 22. APAC: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
Figure 23. China: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Japan: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. India: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Australia: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028List of Tables
Table 1. China: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. China: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product- Revenue and Forecast to 2028 (US$ Million)
Table 3. China Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ million)
Table 4. Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 5. Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product- Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ million)
Table 7. India: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type- Revenue and Forecast to 2028 (US$ Million)
Table 8. India: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product- Revenue and Forecast to 2028 (US$ Million)
Table 9. India Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ million)
Table 10. Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 11. Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product - Revenue and Forecast to 2028 (US$ Million)
Table 12. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ million)
Table 13. South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 14. South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product - Revenue and Forecast to 2028 (US$ Million)
Table 15. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ million)
Table 16. Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product - Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, by End User - Revenue and Forecast to 2028 (US$ million)
Table 19. Recent Inorganic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 20. Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 21. Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ImaginAb
- Curium
- Jubilant Radiopharma
- ABX advanced biochemical compounds GmbH
- Telix Pharmaceuticals Ltd
- Novartis AG
- Lantheus Medical Imaging, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | August 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 156.1 Million |
| Forecasted Market Value ( USD | $ 295.37 Million |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Asia Pacific |
